Last reviewed · How we verify
BV100
At a glance
| Generic name | BV100 |
|---|---|
| Also known as | Rifabutin for Infusion |
| Sponsor | BioVersys AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE2)
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 (PHASE1)
- A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment (PHASE1)
- PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB (PHASE2)
- A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants (PHASE1)
- To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100 (PHASE1)
- Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BV100 CI brief — competitive landscape report
- BV100 updates RSS · CI watch RSS
- BioVersys AG portfolio CI